United States to India: Ras Import Trade Route

The United States to India Ras corridor is one of India's established pharmaceutical import routes from United States, with 382 shipments documented worth a combined $6.0M USD. The route is dominated by JUPITER RESERCH SERVICES INC, which alone accounts for roughly 38% of all import value, reflecting the consolidated nature of United States's ras export sector.

Across 75 active United States suppliers, the average shipment value stands at $15.8K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 76% of all shipments, consistent with ras's non-urgent bulk-order profile.

Shipment activity peaks during January–March, with an average transit time of 19 days port-to-port. The route has recorded an annual growth rate of 14.5%, placing it at rank #6 among India's top ras import origins globally.

On the Indian buyer side, key Indian importers include CURATEQ BIOLOGICS PRIVATE LIMITED, SANOFI HEALTHCARE INDIA PRIVATE LIMITED, INTAS PHARMACEUTICALS LIMITED and 77 others. CURATEQ BIOLOGICS PRIVATE LIMITED is the single largest Indian importer with 4 shipments valued at $2.3M USD.

India's ras imports from United States are driven primarily by a handful of large-scale United States manufacturers. JUPITER RESERCH SERVICES INC with 1 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 75 active exporters signals a competitive but concentrated market — Indian buyers benefit from United States supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — JUPITER RESERCH SERVICES INC, SANOFI-AVENTIS SINGAPORE PTE LTD, ADIRAMEDICA LLC — together account for 75% of total trade value on this route. The average shipment value of $15.8K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as cerezyme 400 iu / 10 ml (imiglucerase for injection) (list 3sr. no. 106)(pac) and trastuzumab hyaluronidase oysk injection for subcutaneouse use herceptin hylecta 600mg trastuzumab 10 000 units hyatrastuzumab hyaluronidase oysk injection for subcutaneous, suggesting that Indian buyers tend to consolidate orders across related product lines from the same United States supplier.

On the buying side, CURATEQ BIOLOGICS PRIVATE LIMITED is the largest importer with 4 shipments worth $2.3M USD — representing 39% of all ras imports from United States on this route. A total of 80 buyers are active on this corridor.